NCT05483894 (STAPH) is a Phase 2 clinical trial of Atorvastatin 10mg in Hepatitis B, sponsored by Samsung Medical Center.

Who is sponsoring NCT05483894?

NCT05483894 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT05483894?

Interventions in NCT05483894: Atorvastatin 10mg, Placebo.

What condition does NCT05483894 study?

NCT05483894 studies Hepatitis B, Portal Hypertension.

Is NCT05483894 still recruiting?

NCT05483894 is currently status unknown. Last updated 2 August 2022.

Last reviewed 2022-08-02 · How we verify

NCT05483894: STAPH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial

Status unknown Phase 2 Last updated 2 August 2022

What this trial tests

Phase 2 trial testing Atorvastatin 10mg in Hepatitis B in 36 participants. Status unknown.

Timeline

1 August 2022

Primary endpoint
31 July 2024

31 January 2025

Quick facts

Lead sponsor	Samsung Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	36
Start date	1 August 2022
Primary completion	31 July 2024
Estimated completion	31 January 2025

Drugs / interventions tested

Atorvastatin 10mg — full drug profile →
Placebo

Conditions studied

Hepatitis B — all drugs for Hepatitis B →
Portal Hypertension — all drugs for Portal Hypertension →

Sponsor

Samsung Medical Center

Who can join

Adults 19 to 69, any sex, with Hepatitis B or Portal Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate whether atorvastatin can improve portal hypertension in patients with chronic hepatitis B related compensated cirrhosis with portal hypertension

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Atorvastatin 10mg

Trials testing the same drug.

NCT05289063 — Vascular Endothelial Dysfunction in Sleep Apnea · Phase 1 · recruiting
NCT05970679 — Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A · Phase 3 · completed
NCT03692754 — Atorvastatin in Management of Newly Diagnosed ITP · Phase 2, PHASE3 · unknown
NCT04072601 — Statins for Prevention of Disease Progression and Hospitalization in Liver Cirrhosis · Phase 4 · terminated
NCT03906539 — Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in Patients With Dyslipidemia · Phase 4 · completed

Other recruiting trials for Hepatitis B

Currently open trials in the same condition.

NCT04843852 — TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B · Phase 1 · recruiting
NCT07168356 — A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease · Phase 1 · recruiting
NCT06947356 — Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads · NA · recruiting
NCT06537414 — A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living Wit · Phase 2 · active not recruiting
NCT06623071 — Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation FA 96/384 · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05483894 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 2 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05483894.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing